Smith & Nephew plc (LON:SN - Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 1,037.30 ($14.12) and traded as high as GBX 1,127 ($15.34). Smith & Nephew shares last traded at GBX 1,107.50 ($15.08), with a volume of 1,028,306 shares.
Smith & Nephew Stock Up 0.2%
The business has a 50-day simple moving average of GBX 1,042.73 and a 200-day simple moving average of GBX 1,038.78. The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51. The company has a market cap of £12.28 billion, a price-to-earnings ratio of 40.34, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62.
Insider Activity at Smith & Nephew
In related news, insider Jeremy (Jez) Maiden bought 1,855 shares of the company's stock in a transaction that occurred on Thursday, May 1st. The shares were purchased at an average cost of GBX 1,070 ($14.57) per share, with a total value of £19,848.50 ($27,023.14). Also, insider Sybella Stanley purchased 3,810 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average price of GBX 1,101 ($14.99) per share, for a total transaction of £41,948.10 ($57,111.10). 0.19% of the stock is owned by corporate insiders.
About Smith & Nephew
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Featured Articles
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
